269 related articles for article (PubMed ID: 37944912)
21. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
22. Clinical and economic impact of molecular testing for BRAF fusion in pediatric low-grade Glioma.
Rios JD; Velummailum R; Bennett J; Nobre L; Tsang DS; Bouffet E; Hawkins C; Tabori U; Denburg A; Pechlivanoglou P
BMC Pediatr; 2022 Jan; 22(1):13. PubMed ID: 34980048
[TBL] [Abstract][Full Text] [Related]
23. Pediatric low-grade gliomas and the need for new options for therapy: Why and how?
Qaddoumi I; Sultan I; Broniscer A
Cancer Biol Ther; 2009 Jan; 8(1):4-10. PubMed ID: 19164945
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: an analysis of the Surveillance Epidemiology and End Results (SEER) database.
Bandopadhayay P; Bergthold G; London WB; Goumnerova LC; Morales La Madrid A; Marcus KJ; Guo D; Ullrich NJ; Robison NJ; Chi SN; Beroukhim R; Kieran MW; Manley PE
Pediatr Blood Cancer; 2014 Jul; 61(7):1173-9. PubMed ID: 24482038
[TBL] [Abstract][Full Text] [Related]
25. A Molecular Update and Review of Current Trials in Paediatric Low-Grade Gliomas.
Al-Jilaihawi S; Lowis S
Pediatr Neurosurg; 2023; 58(5):290-298. PubMed ID: 37604126
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of mTORC1 in pediatric low-grade glioma depletes glutathione and therapeutically synergizes with carboplatin.
Poore B; Yuan M; Arnold A; Price A; Alt J; Rubens JA; Slusher BS; Eberhart CG; Raabe EH
Neuro Oncol; 2019 Feb; 21(2):252-263. PubMed ID: 30239952
[TBL] [Abstract][Full Text] [Related]
27. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
28. Advances in pediatric gliomas: from molecular characterization to personalized treatments.
Sathyakumar S; Martinez M; Perreault S; Legault G; Bouffet E; Jabado N; Larouche V; Renzi S
Eur J Pediatr; 2024 Jun; 183(6):2549-2562. PubMed ID: 38558313
[TBL] [Abstract][Full Text] [Related]
29. BRAF Status in Personalizing Treatment Approaches for Pediatric Gliomas.
Olow A; Mueller S; Yang X; Hashizume R; Meyerowitz J; Weiss W; Resnick AC; Waanders AJ; Stalpers LJ; Berger MS; Gupta N; James CD; Petritsch CK; Haas-Kogan DA
Clin Cancer Res; 2016 Nov; 22(21):5312-5321. PubMed ID: 27217440
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact of combined epigenetic and molecular analysis of pediatric low-grade gliomas.
Fukuoka K; Mamatjan Y; Tatevossian R; Zapotocky M; Ryall S; Stucklin AG; Bennett J; Nobre LF; Arnoldo A; Luu B; Wen J; Zhu K; Leon A; Torti D; Pugh TJ; Hazrati LN; Laperriere N; Drake J; Rutka JT; Dirks P; Kulkarni AV; Taylor MD; Bartels U; Huang A; Zadeh G; Aldape K; Ramaswamy V; Bouffet E; Snuderl M; Ellison D; Hawkins C; Tabori U
Neuro Oncol; 2020 Oct; 22(10):1474-1483. PubMed ID: 32242226
[TBL] [Abstract][Full Text] [Related]
31. Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study.
Lassaletta A; Scheinemann K; Zelcer SM; Hukin J; Wilson BA; Jabado N; Carret AS; Lafay-Cousin L; Larouche V; Hawkins CE; Pond GR; Poskitt K; Keene D; Johnston DL; Eisenstat DD; Krishnatry R; Mistry M; Arnoldo A; Ramaswamy V; Huang A; Bartels U; Tabori U; Bouffet E
J Clin Oncol; 2016 Oct; 34(29):3537-3543. PubMed ID: 27573663
[TBL] [Abstract][Full Text] [Related]
32. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T
Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331
[TBL] [Abstract][Full Text] [Related]
33. CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles.
Jain P; Fierst TM; Han HJ; Smith TE; Vakil A; Storm PB; Resnick AC; Waanders AJ
Oncogene; 2017 Nov; 36(45):6348-6358. PubMed ID: 28806393
[TBL] [Abstract][Full Text] [Related]
34. Management of pediatric low-grade glioma.
de Blank P; Bandopadhayay P; Haas-Kogan D; Fouladi M; Fangusaro J
Curr Opin Pediatr; 2019 Feb; 31(1):21-27. PubMed ID: 30531227
[TBL] [Abstract][Full Text] [Related]
35. Generation of patient-derived pediatric pilocytic astrocytoma in-vitro models using SV40 large T: evaluation of a modeling workflow.
Selt F; El Damaty A; Schuhmann MU; Sigaud R; Ecker J; Sievers P; Kocher D; Herold-Mende C; Oehme I; von Deimling A; Pfister SM; Sahm F; Jones DTW; Witt O; Milde T
J Neurooncol; 2023 Dec; 165(3):467-478. PubMed ID: 37999877
[TBL] [Abstract][Full Text] [Related]
36. LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.
Hardin EC; Schmid S; Sommerkamp A; Bodden C; Heipertz AE; Sievers P; Wittmann A; Milde T; Pfister SM; von Deimling A; Horn S; Herz NA; Simon M; Perera AA; Azizi A; Cruz O; Curry S; Van Damme A; Garami M; Hargrave D; Kattamis A; Kotnik BF; Lähteenmäki P; Scheinemann K; Schouten-van Meeteren AYN; Sehested A; Viscardi E; Wormdal OM; Zapotocky M; Ziegler DS; Koch A; Hernáiz Driever P; Witt O; Capper D; Sahm F; Jones DTW; van Tilburg CM
Neuro Oncol; 2023 Nov; 25(11):2087-2097. PubMed ID: 37075810
[TBL] [Abstract][Full Text] [Related]
37. Optimizing preclinical pediatric low-grade glioma models for meaningful clinical translation.
Milde T; Fangusaro J; Fisher MJ; Hawkins C; Rodriguez FJ; Tabori U; Witt O; Zhu Y; Gutmann DH
Neuro Oncol; 2023 Nov; 25(11):1920-1931. PubMed ID: 37738646
[TBL] [Abstract][Full Text] [Related]
38. MOST wanted: navigating the MAPK-OIS-SASP-tumor microenvironment axis in primary pediatric low-grade glioma and preclinical models.
Sigaud R; Brummer T; Kocher D; Milde T; Selt F
Childs Nerv Syst; 2024 May; ():. PubMed ID: 38789691
[TBL] [Abstract][Full Text] [Related]
39. Retrospective and integrative analyses of molecular characteristics and their specific imaging parameters in pediatric grade 1 gliomas.
Coutant M; Lhermitte B; Guérin E; Chammas A; Reita D; Sebastia C; Douzal V; Gabor F; Salmon A; Chenard MP; Todeschi J; Coca A; Heng MA; Vincent F; Entz-Werlé N
Pediatr Blood Cancer; 2022 Aug; 69(8):e29575. PubMed ID: 35373885
[TBL] [Abstract][Full Text] [Related]
40. Evaluating the safety of perioperative dexamethasone treatment: A retrospective analysis of a single center pediatric low-grade glioma cohort.
Gorodezki D; Zipfel J; Queudeville M; Holzer U; Bevot A; Schittenhelm J; Nägele T; Schuhmann MU; Ebinger M
Int J Cancer; 2023 May; 152(9):1875-1883. PubMed ID: 36522830
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
